{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:10:40Z","timestamp":1790809840365,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s11060-023-04460-x","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T15:01:31Z","timestamp":1696431691000},"page":"655-662","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Risk of developing glioblastoma following non-CNS primary cancer: a SEER analysis between 2000 and 2018"],"prefix":"10.1007","volume":"164","author":[{"given":"David Y. A.","family":"Dadey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary A.","family":"Medress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Ugiliweneza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Summer S.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Boakye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Skirboll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,4]]},"reference":[{"issue":"5","key":"4460_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3109\/02841869709001300","volume":"36","author":"JE Frodin","year":"1997","unstructured":"Frodin JE, Ericsson J, Barlow L (1997) Multiple primary malignant tumors in a national cancer registry\u2013reliability of reporting. Acta Oncologica (Stockholm, Sweden) 36(5):465\u2013469","journal-title":"Acta Oncologica (Stockholm, Sweden)"},{"issue":"1","key":"4460_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/S0959-8049(98)00341-4","volume":"35","author":"E Salminen","year":"1999","unstructured":"Salminen E, Pukkala E, Teppo L (1999) Second cancers in patients with brain tumours\u2013impact of treatment. Eur J Cancer 35(1):102\u2013105","journal-title":"Eur J Cancer"},{"key":"4460_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12885-015-1426-3","volume":"15","author":"KD Lee","year":"2015","unstructured":"Lee KD, Chen CY, Huang HJ et al (2015) Increased risk of second primary malignancies following uterine cancer: a population-based study in Taiwan over a 30-year period. BMC Cancer. 15:393. https:\/\/doi.org\/10.1186\/s12885-015-1426-3","journal-title":"BMC Cancer."},{"issue":"2","key":"4460_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s11523-016-0459-0","volume":"12","author":"VY Su","year":"2017","unstructured":"Su VY, Liu CJ, Chen YM et al (2017) Risk of second primary malignancies in lung cancer survivors\u2014the influence of different treatments. Target Oncol 12(2):219\u2013227. https:\/\/doi.org\/10.1007\/s11523-016-0459-0","journal-title":"Target Oncol"},{"issue":"2","key":"4460_CR5","doi-asserted-by":"publisher","first-page":"e0148597","DOI":"10.1371\/journal.pone.0148597","volume":"11","author":"MH Hung","year":"2016","unstructured":"Hung MH, Liu CJ, Teng CJ et al (2016) Risk of second non-breast primary cancer in male and female breast cancer patients: a population-based cohort study. PLoS ONE 11(2):e0148597. https:\/\/doi.org\/10.1371\/journal.pone.0148597","journal-title":"PLoS ONE"},{"key":"4460_CR6","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.2147\/ott.S129220","volume":"10","author":"J Yang","year":"2017","unstructured":"Yang J, Li S, Lv M et al (2017) Risk of subsequent primary malignancies among patients with prior colorectal cancer: a population-based cohort study. Onco Targets Ther 10:1535\u20131548. https:\/\/doi.org\/10.2147\/ott.S129220","journal-title":"Onco Targets Ther"},{"issue":"11","key":"4460_CR7","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1245\/s10434-014-3774-7","volume":"21","author":"RM Kauffmann","year":"2014","unstructured":"Kauffmann RM, Wang L, Phillips S, Idrees K, Merchant NB, Parikh AA (2014) Incidence of additional primary malignancies in patients with pancreatic and gastrointestinal neuroendocrine tumors. J Ann Surg Oncol 21(11):3422\u20133428. https:\/\/doi.org\/10.1245\/s10434-014-3774-7","journal-title":"J Ann Surg Oncol"},{"issue":"2","key":"4460_CR8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/cncr.29025","volume":"121","author":"YY Cho","year":"2015","unstructured":"Cho YY, Lim J, Oh CM et al (2015) Elevated risks of subsequent primary malignancies in patients with thyroid cancer: a nationwide, population-based study in Korea. Cancer 121(2):259\u2013268. https:\/\/doi.org\/10.1002\/cncr.29025","journal-title":"Cancer"},{"key":"4460_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.wneu.2017.02.104","volume":"102","author":"F Gessler","year":"2017","unstructured":"Gessler F, Zappi J, Konczalla J et al (2017) Secondary glioblastoma: molecular and clinical factors that affect outcome after malignant progression of a lower grade tumor. World Neurosurgery 102:49\u201355. https:\/\/doi.org\/10.1016\/j.wneu.2017.02.104","journal-title":"World Neurosurgery"},{"issue":"2","key":"4460_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11060-017-2415-y","volume":"133","author":"C Hamisch","year":"2017","unstructured":"Hamisch C, Ruge M, Kellermann S et al (2017) Impact of treatment on survival of patients with secondary glioblastoma. J Neurooncol 133(2):309\u2013313. https:\/\/doi.org\/10.1007\/s11060-017-2415-y","journal-title":"J Neurooncol"},{"issue":"3","key":"4460_CR11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s11060-015-1992-x","volume":"126","author":"MA Hamza","year":"2016","unstructured":"Hamza MA, Kamiya-Matsuoka C, Liu D, Yuan Y et al (2016) Outcome of patients with malignant glioma and synchronous or metachronous non-central nervous system primary neoplasms. J Neuro-Oncol. 126(3):527\u2013533. https:\/\/doi.org\/10.1007\/s11060-015-1992-x","journal-title":"J Neuro-Oncol."},{"issue":"19","key":"4460_CR12","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1200\/jco.2007.11.3530","volume":"25","author":"RA Freedman","year":"2007","unstructured":"Freedman RA, Wirth LJ, Chirieac LR, Huang EC (2007) Glioblastoma in a patient with early-stage tonsil cancer. J Clin Oncol 25(19):2848\u20132850. https:\/\/doi.org\/10.1200\/jco.2007.11.3530","journal-title":"J Clin Oncol"},{"issue":"1","key":"4460_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4048\/jbc.2017.20.1.108","volume":"20","author":"A Raufi","year":"2017","unstructured":"Raufi A, Alsharedi M, Khelfa Y, Tirona M (2017) Bilateral triple-negative invasive breast cancer with a BRCA2 mutation, and glioblastoma: a case report and literature review. J Breast Cancer 20(1):108\u2013111. https:\/\/doi.org\/10.4048\/jbc.2017.20.1.108","journal-title":"J Breast Cancer"},{"issue":"6","key":"4460_CR14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/BF00300851","volume":"4","author":"L Poyhonen","year":"1979","unstructured":"Poyhonen L, Heikkinen J, Vehkalahti I (1979) Two different primary tumours of the brain in a patient with breast cancer. Eur J Nucl Med 4(6):483\u2013484","journal-title":"Eur J Nucl Med"},{"key":"4460_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12885-015-1205-1","volume":"15","author":"M Boukerroucha","year":"2015","unstructured":"Boukerroucha M, Josse C, Segers K et al (2015) BRCA1 germline mutation and glioblastoma development: report of cases. BMC Cancer 15:181. https:\/\/doi.org\/10.1186\/s12885-015-1205-1","journal-title":"BMC Cancer"},{"issue":"3","key":"4460_CR16","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0090-3019(95)00305-3","volume":"45","author":"M Nagane","year":"1996","unstructured":"Nagane M, Shibui S, Nishikawa R, Oyama H, Nakanishi Y, Nomura K (1996) Triple primary malignant neoplasms including a malignant brain tumor: report of two cases and review of the literature. Surg Neurol 45(3):219\u2013229","journal-title":"Surg Neurol"},{"issue":"3","key":"4460_CR17","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1177\/030089160509100309","volume":"91","author":"M Piccirilli","year":"2005","unstructured":"Piccirilli M, Salvati M, Bistazzoni S et al (2005) Glioblastoma multiforme and breast cancer: report on 11 cases and clinico-pathological remarks. Tumori 91(3):256\u2013260","journal-title":"Tumori"},{"issue":"1","key":"4460_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11060-018-03028-4","volume":"141","author":"HS Nguyen","year":"2019","unstructured":"Nguyen HS, Doan NB, Gelsomino M et al (2019) Management and survival trends for adult patients with malignant gliomas in the setting of multiple primary tumors: a population based analysis. J Neurooncol 141(1):213\u2013221. https:\/\/doi.org\/10.1007\/s11060-018-03028-4","journal-title":"J Neurooncol"},{"issue":"17","key":"4460_CR19","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1001\/jama.2013.280319","volume":"310","author":"A Omuro","year":"2013","unstructured":"Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. JAMA 310(17):1842\u20131850. https:\/\/doi.org\/10.1001\/jama.2013.280319","journal-title":"JAMA"},{"issue":"5","key":"4460_CR20","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.2353\/ajpath.2007.070011","volume":"170","author":"H Ohgaki","year":"2007","unstructured":"Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170(5):1445\u20131453. https:\/\/doi.org\/10.2353\/ajpath.2007.070011","journal-title":"Am J Pathol"},{"issue":"9","key":"4460_CR21","doi-asserted-by":"publisher","first-page":"7318","DOI":"10.18632\/oncotarget.3440","volume":"6","author":"R Li","year":"2015","unstructured":"Li R, Li H, Yan W et al (2015) Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution. Oncotarget 6(9):7318\u20137324. https:\/\/doi.org\/10.18632\/oncotarget.3440","journal-title":"Oncotarget"},{"key":"4460_CR22","volume-title":"New malignancies among cancer survivors: SEER cancer registries, 1973\u20132000","year":"2006","unstructured":"Curtis RE, Freedman DM, Ron E et al (eds) (2006) New malignancies among cancer survivors: SEER cancer registries, 1973\u20132000. National Cancer Institute"},{"key":"4460_CR23","first-page":"1","volume":"82","author":"NEN Breslow","year":"1987","unstructured":"Breslow NEN (1987) Statistical methods in cancer research: volume II\u2014the design and analysis of cohort studies. IARC Sci Pub 82:1\u2013406","journal-title":"IARC Sci Pub"},{"issue":"6","key":"4460_CR24","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.annepidem.2014.02.010","volume":"24","author":"PM Scarbrough","year":"2014","unstructured":"Scarbrough PM, Akushevich I, Wrensch M, Il\u2019yasova D (2014) Exploring the association between melanoma and glioma risks. Ann Epidemiol 24(6):469\u2013474. https:\/\/doi.org\/10.1016\/j.annepidem.2014.02.010","journal-title":"Ann Epidemiol"},{"issue":"8","key":"4460_CR25","doi-asserted-by":"publisher","first-page":"e0203058","DOI":"10.1371\/journal.pone.0203058","volume":"13","author":"F Schad","year":"2018","unstructured":"Schad F, Thronicke A, Steele ML et al (2018) Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L in addition to chemotherapy, a real-world observational multicenter analysis. PloS One. 13(8):e0203058\u2013e0203058. https:\/\/doi.org\/10.1371\/journal.pone.0203058","journal-title":"PloS One."},{"issue":"1","key":"4460_CR26","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1017\/s0317167100007642","volume":"35","author":"JL Steckley","year":"2008","unstructured":"Steckley JL, Watling CJ, Ng W (2008) Glioblastoma in a patient with a hereditary cancer syndrome. Can J Neurol Sci 35(1):98\u2013101. https:\/\/doi.org\/10.1017\/s0317167100007642","journal-title":"Can J Neurol Sci"},{"issue":"10","key":"4460_CR27","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.neurol.2019.08.004","volume":"175","author":"A Vienne-Jumeau","year":"2019","unstructured":"Vienne-Jumeau A, Tafani C, Ricard D (2019) Environmental risk factors of primary brain tumors: a review. Rev Neurol (Paris) 175(10):664\u2013678. https:\/\/doi.org\/10.1016\/j.neurol.2019.08.004","journal-title":"Rev Neurol (Paris)"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04460-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-023-04460-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04460-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T13:06:39Z","timestamp":1697807199000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-023-04460-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["4460"],"URL":"https:\/\/doi.org\/10.1007\/s11060-023-04460-x","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"23 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have not disclosed any competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"This study was approved by the Internal Review Board of the University of Louisville and Stanford University. SEER data is publicly available after an approval process. The data is de-identified and analysis does not require informed consent. We obtained permission to access the research data file in the SEER program by National Cancer Institute, USA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}